Literature DB >> 21686754

Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours.

C Daousi1, Patrick M Foy, Ian A Macfarlane.   

Abstract

Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours. It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid tumour expansion. We studied the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas. Patients studied were: (1) a female with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma. Changes in tumour size on serial magnetic resonance imaging scans, and restoration of euthyroidism were studied. No marked changes in tumour size or features of aggressiveness occurred in these patients over periods of 8 and 12 years. Euthyroidism was restored and maintained in both patients. Ablative thyroid treatment can be a safe and successful option to treat TSHomas.

Entities:  

Year:  2009        PMID: 21686754      PMCID: PMC3029586          DOI: 10.1136/bcr.07.2008.0541

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  Thyrotropin-secreting pituitary tumors.

Authors:  P Beck-Peccoz; F Brucker-Davis; L Persani; R C Smallridge; B D Weintraub
Journal:  Endocr Rev       Date:  1996-12       Impact factor: 19.871

2.  Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.

Authors:  J M Kuhn; S Arlot; H Lefebvre; P Caron; C Cortet-Rudelli; F Archambaud; P Chanson; A Tabarin; M I Goth; J Blumberg; F Catus; S Ispas; P Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

3.  Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health.

Authors:  F Brucker-Davis; E H Oldfield; M C Skarulis; J L Doppman; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

4.  Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

Authors:  A Gancel; P Vuillermet; A Legrand; F Catus; F Thomas; J M Kuhn
Journal:  Clin Endocrinol (Oxf)       Date:  1994-03       Impact factor: 3.478

5.  Thyrotropin-releasing hormone (TRH) binding sites and thyrotropin response to TRH are regulated by thyroid hormones in human thyrotropic adenomas.

Authors:  M Le Dafniet; A M Brandi; M Kujas; P Chanson; F Peillon
Journal:  Eur J Endocrinol       Date:  1994-06       Impact factor: 6.664

6.  Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.

Authors:  P Chanson; B D Weintraub; A G Harris
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

7.  Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.

Authors:  R J Comi; N Gesundheit; L Murray; P Gorden; B D Weintraub
Journal:  N Engl J Med       Date:  1987-07-02       Impact factor: 91.245

8.  A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies.

Authors:  P Jaquet; J Hassoun; P Delori; G Gunz; F Grisoli; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1984-11       Impact factor: 5.958

9.  Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995.

Authors:  P Beck-Peccoz; S Mariotti; P J Guillausseau; G Medri; G Piscitelli; A Bertoli; A Barbarino; M Rondena; P Chanson; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

10.  Hyperthyroidism secondary to a pituitary adenoma secreting TSH, FSH, alpha-subunit and GH.

Authors:  A W Patrick; S L Atkin; J MacKenzie; P M Foy; M C White; I A MacFarlane
Journal:  Clin Endocrinol (Oxf)       Date:  1994-02       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.